Advertisement

Topics

Study of Dust Mite Inhalation in Humans

2014-08-27 03:39:36 | BioPortfolio

Summary

The purpose of this research study is to learn more about the effect of inhaled dust mite allergen extract on airway responses in allergic individuals with mild asthma. Information learned from this study will be used to identify a safe dose range of D Farinae extract for use in inhalation challenge studies. This study will also help determine how inhalation of the allergen affects mucociliary clearance (MCC) which is a measure of how quickly mucus clears from the airway.

Description

This will be a non-blinded study of the effect of inhaled house dust mite (D Farinae) allergen extract on airway responses, with the principal endpoint being a decrease in FEV1 of 15% within 10 minutes after inhalation of one of a sequence of doses of allergen compared with measurements obtained immediately prior to challenge These doses will be delivered as 5 inhalations of allergen at concentrations of 0.25, 0.50, 1.0, 2.0, 4.0, 8.0, 16, 32, 64, 125, 250, 500, 1000, and 2000 AU/mL. Allergen challenge often induces an immediate and late phase decrease in lung function. The immediate phase that occurs within 10 minutes, often self resolves and is associated with release of histamine from airway mast cells, while the late phase response often occurs 2 to 8 hours later and is associated with increased airway inflammation.

During the subject's baseline visit occurring at least 2 days prior to allergen challenge, we will measure mucociliary clearance (MCC) of inhaled, radiolabeled particles by gamma scintigraphy. The subject will return 24 hours later for a follow-up scan and a sputum sample will also be collected. At 4 hours post allergen challenge, we will again measure MCC as an exploratory endpoint. It is expected that mucociliary clearance will be depressed as part of a late phase reaction to allergen challenge. Twenty-four hours after allergen challenge, induced sputum will be obtained and compared with the sputum sample obtained at the baseline visit. Exploratory endpoints of interest from examination of induced sputum will also be collected after inhaled allergen challenge.

Observation Schedule (details regarding study procedures follow below):

Baseline visit

1. Consent will be obtained

2. Review of subject's medical history and current medications

3. Vital sign measurements (temperature, pulse, respiratory rate, blood pressure), oxygen saturation, and symptom scoring

4. Urine pregnancy test for women of child bearing potential

5. Spirometry

6. Physical exam of the ears, nose, throat and chest

7. Xenon equilibrium gas scan

8. Mucociliary clearance procedure (MCC)

24 hours post baseline visit

1. Review any change in medical status over prior 24 hours

2. Vital signs, oxygen saturation and symptom score

3. Follow up MCC scan

4. Sputum induction

Post Challenge Observations/Reporting Subjects will be contacted for phone call follow-up 24 hours after sputum induction (see accompanying phone script)

24-48 hours prior to challenge visit (at least 2 days after the baseline visit)

1. Review any change in medical status since last visit

2. Vital signs, oxygen saturation, and symptom score

3. Spirometry

4. Physical exam of the ears, nose, throat and chest

Allergen challenge day

1. Review any change in medical status since last visit

2. Vital signs, oxygen saturation, and symptom score

3. Urine pregnancy test

4. Spirometry

5. If above measures are acceptable, allergen challenge will be performed as described

6. Post-challenge monitoring at intervals indicated on study worksheets

7. Four hours post challenge, subject will have MCC evaluated

8. Overnight stay in the UNC General Clinical Research Center (GCRC). Subjects will be instructed to perform either spirometry with a personal spirometer or peak flow assessments on an every other hourly basis until at least 9 pm, and up to 11 pm if the subject is awake.

24 hours post challenge

1. Subject is discharged from GCRC, and accompanied by a study staff member, proceeds directly to CEMALB.

2. Vital signs, oxygen saturation, and symptom score

3. Spirometry

4. Follow-up MCC scan

5. Sputum induction

Post Challenge Observations/Reporting

1. Subjects will be contacted for phone call follow-up 24 hours after post-challenge sputum induction (see accompanying phone script)

2. Each volunteer will be given a symptom scoring sheet for each day up to 96 hours (4 days) after challenge (see accompanying symptom scoring sheet).

Study discontinuation visit within 10 days of the final challenge dose:

1. Vital signs, oxygen saturation, and symptom score

2. Spirometry

3. If any findings are abnormal, medical evaluation as directed by the study physician will be undertaken

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label

Conditions

Mild Asthma

Intervention

inhaled allergen challenge

Location

UNC Center for Environmental Medicine, Asthma and Lung Biology
Chapel Hill
North Carolina
United States
27599-7310

Status

Recruiting

Source

University of North Carolina, Chapel Hill

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:39:36-0400

Clinical Trials [2386 Associated Clinical Trials listed on BioPortfolio]

A Study to Evaluate the Effect of GW870086X on Allergen Challenge in Mild Asthmatics

The study will measure the early and late asthamtic response using an allergen challenge. This study will evaluate the safety and patients tolerance to repeat inhaled doses of GW870086X us...

Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination and FF on an Allergen Induced Asthmatic Response

We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist/ inhaled corticosteroid combination prod...

Early Phase Administration of Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation

Purpose: The primary objective of this study is to examine the effectiveness of anakinra as a rescue treatment for allergic airway inflammation. Utilizing an inhaled allergen challenge mod...

Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation

Purpose: The primary objective of this study is to examine the effectiveness of anakinra as a rescue treatment for allergic airway inflammation. Utilizing an inhaled allergen challenge mod...

CysLT1-r Expression Following Allergen Exposure in Asthma and Allergic Rhinitis

Cysteinyl leukotrienes (CysLTs) play an important role in asthma. CysLTs exert most of their bronchoconstrictive and pro-inflammatory effects through activation of the CysLT1-r. As allergi...

PubMed Articles [6286 Associated PubMed Articles listed on BioPortfolio]

Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma.

In patients with mild asthma, as-needed use of an inhaled glucocorticoid plus a fast-acting β-agonist may be an alternative to conventional treatment strategies.

IL-33 and Its Receptor ST2 after Inhaled Allergen Challenge in Allergic Asthmatics.

Previous murine models have demonstrated interleukin (IL)-33 to be an important mediator of type-2 inflammation and to promote airway hyperresponsiveness in allergic asthma. A number of inflammatory c...

As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma.

Patients with mild asthma often rely on inhaled short-acting β-agonists for symptom relief and have poor adherence to maintenance therapy. Another approach might be for patients to receive a fast-act...

Inhaled corticosteroids and asthma control in adult-onset asthma: 12-year follow-up study.

Prescribed inhaled corticosteroid (ICS) doses in asthma have been studied in cross-sectional settings whereas long-term follow-up studies have not been carried out.

Environmental Causes of Asthma.

Environmental factors which cause asthma are those that induce airway inflammation with eosinophils (more common) or neutrophils along with airway hyperresponsiveness (AHR). The most common of these (...

Medical and Biotech [MESH] Definitions

A plant genus of the family POACEAE that contains the Poa p Ia allergen and allergen C KBGP.

A quantitative form of intradermal testing for the relative allergenicity of a substance. It is used to determine the amount of an allergen that will be tolerated in ALLERGEN IMMUNOTHERAPY.

A pharmaceutical preparation of mometasone furoate and formoterol fumarate that is used as an inhaled dosage form for the treatment of ASTHMA.

Illicit use of chemicals and products whose vapors can be inhaled to produce a rapid mind-altering effect. Inhalants include aerosols, gases, and volatile solvents that are often inhaled repeatedly to achieve the short-lived intoxicating effect.

Asthma attacks caused, triggered, or exacerbated by OCCUPATIONAL EXPOSURE.

More From BioPortfolio on "Study of Dust Mite Inhalation in Humans"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Asthma
Asthma is caused by inflammation of small tubes, called bronchi, which carry air in and out of the lungs. If you have asthma, the bronchi will be inflamed and more sensitive than normal.  When you come into contact with something that irritates your...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...


Searches Linking to this Trial